Isofol Medical AB
Research Isofol Medical AB (ISOFOL) on Bullrun: market cap SEK 246.46M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerISOFOL
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 246.46M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 15.06M
- Free cash flow-SEK 16.42M
Valuation Snapshot
latest market cap is SEK 246.46M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 54.17M | -SEK 51.94M | n/a | -0.26 | SEK 41.99M | n/a | SEK 107.87M |
| FY2022 | SEK 12.80M | -SEK 159.76M | -SEK 190.98M | n/a | -0.99 | SEK 190.58M | n/a | SEK 158.48M |
| FY2021 | SEK 22.41M | -SEK 200.25M | -SEK 188.43M | n/a | -1.59 | SEK 379.45M | n/a | SEK 318.23M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-05 | SEK 246.46M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Isofol Medical AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Isofol Medical AB's market cap?
Isofol Medical AB's market capitalization is SEK 246.46M.
What does Isofol Medical AB do?
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.